Replies to post #24337 on Biotech Values

[DewDiligence]

Re: INGN phase-1/2 results in lung cancer

http://biz.yahoo.com/prnews/060221/datu058.html?.v=26

>>
Following INGN 225 treatment and chemotherapy, 62% percent of evaluable patients demonstrated objective tumor responses.
<<

Why the heck doesn’t the PR say how many evaluable patients there were?

[DewDiligence]

CVM
You call this impressive?

From today’s PR

http://biz.yahoo.com/prnews/060221/cltu506.html?.v=25

>>
The results of the Phase II trial follow-up study showed that the Multikine-treated patients had substantially increased survival rates and achieved a higher rate of 2-year local regional control as compared to the survival and the 2-year local regional control rates published in the scientific literature (39 clinical trials between 1987 and 2004 in a similar population of head & neck cancer patients). At this time, CEL-SCI cannot provide the detailed results of this long-term follow-up study of Multikine treatment as the data are currently being prepared for publication.
<<

It’s bad enough that CVM trumpets that the results are better than cherry-picked historical controls. Strike one! Then they have the gall to go a step further and not even tell us what the heck the results were! Strike two!

One more strike and these guys are out!